



A⁺ Science Newsletter, October 2014

"We're just enthusiastic about what we do"

Steve Jobs

A+ Science, a CRO run by its employees

Our vision is to become the CRO best known for its unique and dedicated personnel with focus on customer satisfaction. To Earn Trust- Make Difference

In this newsletter we are very proud to introduce you to one of our board members, Helena Erlandsson Harris.

Helena is a Professor in rheumatological inflammation research at Karolinska Institute. She is also PI for a research group at the unit for rheumatology, vice director for the Center for Molecular Medicine at Karolinska Institute and head of the national clinical research school in chronic inflammatory diseases funded by the Swedish Science Council. Helena is also the coordinator for the EU-project 'Counterstroke' which aims at developing a new therapy for Stroke, both academic groups and biotech companies are partners of Counterstroke.

Helena's research interest is the endogenous molecules that initiate the inflammatory cascade, the so-called Alarmins. She studies how they function, how they can contribute to inflammatory diseases and if they can be potential

targets for new therapies. Helena has a particular interest in rheumatic diseases but she also studies other inflammatory conditions such as stroke, cancer, drug-induced liver toxicity and diabetes.

"I believe that a question of outmost importance for the future success of Swedish medical research and the Swedish life science sector is our ability to develop research results into therapies and treatment strategies that reach all the way to the clinical reality.

We must quite simply be better at innovation, in starting new biotech companies and running clinical trials in Sweden. My way to contribute to this in addition to the therapy-focused research I am conducting, is to participate in developing the innovation environment at the Center for Molecular Medicine by different means and to supply the PhD students participating in the national research school an insight into intellectual property rights, bio entrepreneurship and the steps from discovery to clinical trial.

When I was asked to become a board member at A+ Science I considered it as a possibility to further contribute to Swedish Life Science, but also as a fantastic possibility for me personally to get inside knowledge of the conditions for Swedish CRO companies.

My impressions of A+ Science this far is only positive. I sense a strong dedication in the other board members, within the management team and in the employees that I have met so far. A bit of pioneering spirit combined with a strong faith in the future. I hope that I can contribute to a successful future for A+ Science by my experience of clinical medical science, organizational leadership experience and last but not least by some common sense" says Helena Erlandsson Harris.



The Board of Directors at A+ Science consists of Håkan Gartell, Chairman of the Board, Johanna Andlin, Helena Harris Erlandsson and Jennifer Heyno.

The members of the Management Team at A+ Science:

Anna Fröling, CEO/CFO

Eva Stenqvist, Head of Pharmacovigilance

Jennifer Heyno, Lead CTA / Mentor Outsourcing

Suzanne Gunvarsdotter, Manager at City Site

Tania Persson, Business Developer and CME Project Manager

